We collected and analysed data from 99 studies, including a total of 101,311 participants with advanced COPD, using a special method called network meta-analysis, which enabled us to simultaneously compare the four inhaler groups and 28 individual inhalers (4 LABAs, 5 LAMAs, 9 LABA/ICS combinations, and 10 LABA/LAMA combinations). Preventing severe flare-ups and hospital admissions is especially important to people with COPD, healthcare providers, policy makers and society. There are not many head-to-head comparisons to determine which treatment group or individual inhaler is better compared to the others. Combination inhalers are usually reserved for individuals whose single-maintenance inhaler, such as LAMA or LABA fails. The long-acting inhalers are usually reserved for more advanced COPD.ĭoes it matter which long-acting inhaler is used in people with advanced COPD?Ĭommonly used maintenance inhalers are grouped into four different groups: long-acting beta2-agonists (LABAs) long-acting muscarinic antagonists (LAMAs) LABA/inhaled corticosteroid (ICS) combinations and LABA/LAMA combinations. A rescue inhaler is short- and fast-acting, and used as needed for quick relief of symptoms, whereas a maintenance inhaler is long-acting and used on a daily basis to relieve daily symptoms and reduce flare-ups. There are two types of inhalers for COPD: rescue and maintenance. COPD damages the lungs and causes airways to narrow which makes it difficult to breathe. I believe Niveoli™ represents a new paradigm in inhalation therapy.What is COPD and why does a doctor prescribe an inhaler?Ĭhronic obstructive lung disease (COPD) is usually caused by smoking or other airway irritants. In keeping with our purpose of ‘Caring for Life’, we are constantly studying OADs and working towards products that offer greater efficacy, ease of use and drug delivery to patients. We see our market leadership as well as the range and depth of our R&D and manufacturing capabilities in this therapy as a privilege and a responsibility to do more for patients. Be it the transparent dry powder inhaler, the static-free spacer with valve mechanism, the mask-spacer combination for children or our novel breath-actuated inhaler with dose counter called Synchrobreathe™, the list is long. Cipla has a long history of blazing the trail in innovations in combination formulations and drug-device combinations in the respiratory therapy, and Niveoli™ is a painstaking result of these strengths. Niveoli™ marks a first in acknowledging and addressing the issue of drug delivery to the small airways. Niveoli™’s novelty and strength lies in HFA propelled delivery of extra-fine particles of beclomethasone, an inhaled corticosteroid (ICS) and formoterol, a fast-onset long acting beta agonist (LABA) to the small airways.Ĭommenting on the launch, Nikhil Chopra, Head – India business, Cipla, said, “Cipla is pleased to offer yet another milestone in respiratory inhalation therapy. Small airway disease is a common feature of COPD and gets worse with increasing severity of the condition. Another study has indicated that routine lung function tests can underestimate problems in the small airways. A recent meta-analysis showed that small airway disease is prevalent in 50-60% of asthma patients. Extensive research and an evolved understanding of the diseases over the years has shown the significant role of small airway disease in asthma and COPD. Niveoli™ is a proprietary Cipla inhaler, and the latest offering from Cipla in respiratory inhalation therapy that addresses an unmet need associated with obstructive airway diseases (OAD) such as asthma and chronic obstructive pulmonary disorder (COPD).Īsthma and COPD are lung conditions that affect the ability to breathe. Mumbai, Ap– Cipla Limited (BSE: 500087 NSE: CIPLA EQ and hereafter referred to as “Cipla”) announces that it has launched Niveoli™, India’s first extra-fine particle beclomethasone-formoterol combination hydrofluoroalkane (HFA) inhaler for adults, targeting drug delivery to the small airways.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |